Press release

Galenica Santé adds Merfen® and Vita-Merfen® to its OTC product portfolio

Wednesday, 22 February 2017, ↓ directly to download

Galenica Santé adds Merfen® and Vita-Merfen® to its OTC product portfolio

The Galenica Group is further strengthening its OTC product portfolio in the Galenica Santé Business unit. Its subsidiary Vifor Consumer Health is acquiring the two iconic Swiss brands Merfen® and Vita-Merfen® from GSK Consumer Healthcare Schweiz AG. Vifor Consumer Health is therefore entering a new market in the form of wound care and further expanding its position in the Swiss healthcare market.

Read more

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Other recent press releases

contact

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Julien Vignot

Julien Vignot

Head Investor Relations


Galenica Ltd.

Investor Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Send link

Send as link



Links

  •